12:00 AM
 | 
Dec 13, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Resveratrol: Development discontinued

GlaxoSmithKline discontinued development of SRT501 after data from an open-label Phase IIa trial in 24 patients showed that SRT501 displayed only minimal efficacy with the potential to indirectly exacerbate renal complications in MM patients. In April, GSK suspended enrollment in the trial after observing an increase in the incidence of...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >